

Jakub Krejcik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8058992/publications.pdf>

Version: 2024-02-01

10
papers

2,094
citations

1040056

9
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

3001
citing authors

#	ARTICLE	IF	CITATIONS
1	Harnessing the Immune System to Fight Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4546.	3.7	10
2	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN 503): final results of an openâ€label, phase 1/2 study. <i>British Journal of Haematology</i> , 2019, 186, e35-e39.	2.5	12
3	Highâ€Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 279-289.	1.5	117
4	Daratumumab for the Treatment of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 1228.	4.8	59
5	Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma. <i>Oncotarget</i> , 2018, 9, 33621-33622.	1.8	10
6	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. <i>Clinical Cancer Research</i> , 2017, 23, 7498-7511.	7.0	134
7	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2016, 128, 1821-1828.	1.4	98
8	Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. <i>Blood</i> , 2016, 128, 384-394.	1.4	697
9	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 1207-1219.	27.0	948
10	Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma. <i>Blood</i> , 2015, 126, 3037-3037.	1.4	9